Clinical trials: Buccal Cavity Cancer
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
Stomatitis, Oral Mucositis
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
This is a randomized Phase 2 study to evaluate two different steroid-based mouth rinses (Miracle Mouth Wash plus hydrocortisone versus prednisolone oral rinse) for the prevention or treatment of everolimus-associated stomatitis…
- Conditions
- Stomatitis, Oral Mucositis, Neoplasm of the Breast, Malignant Tumor of Breast
- Trial name
- NCT02229136
- Testing
- Miracle Mouthwash Plus Hydrocortisone, Prednisolone
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- US Oncology Research
Carcinoma, Non-small Cell
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or pipe lifetime) or former light smokers …
- Trial name
- NCT00818441
- Testing
- Dacomitinib (PF-00299804)
- Where
- 41 sites in United States, Hong Kong and 3 more
- Volunteers
- 119 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma
The primary aim of this exploratory study is to test the safety and tolerability of milciclib when administered orally at 100 mg in patients with recurrent or metastatic Hepatocellular Carcinoma.
- Trial name
- NCT03109886
- Testing
- Milciclib maleate
- Where
- 14 sites in Greece, Israel and 1 more
- Volunteers
- 31 people
- Sponsor
- Tiziana Life Sciences LTD
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum
Small Cell Lung Cancer
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy.
- Trial name
- NCT00043927
- Testing
- topotecan/cisplatin, etoposide/cisplatin
- Where
- 176 sites in United States, Austria and 32 more
- Volunteers
- 760 people
- Sponsor
- GlaxoSmithKline
Esophageal Cancer, Gastric Cancer
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.
- Conditions
- Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
- Trial name
- NCT05438420
- Testing
- Q702, Pembrolizumab
- Where
- 7 sites in United States, South Korea
- Volunteers
- 120 people
- Sponsor
- Qurient Co., Ltd.
Relapsed or Refractory Multiple Myeloma
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain…
- Trial name
- NCT07728188
- Testing
- Etentamig, Pomalidomide, Daratumumab
- Where
- 66 sites in United States, Australia and 11 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Oncology
The Effect of Amorphous Calcium Carbonate (ACC) Treatment on Function and Welfare in Late-stage Solid Cancer Subjects
An exploratory open label study to improve the function and welfare of late-stage solid cancer subjects (with or without lung involvement) who failed or refused anti-cancer treatment by ACC treatment, administered orally and…
- Trial name
- ONCO-004-1 (NCT03582280)
- Testing
- Amorphous Calcium Carbonate (ACC) - Amor
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Amorphical Ltd.
Advanced Solid Tumors
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309
This study is a Phase I, open label study to determine the Maximum Tolerated Dose(MTD) and the Recommended Phase II Dose (RP2D) in patients with advanced solid tumors.
- Trial name
- NCT01940133
- Testing
- PQR309
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- PIQUR Therapeutics AG
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
The overall purpose of this phase II trial was to evaluate the efficacy of 250 mg BIBF 1120 twice daily (BID) versus 150 mg BIBF 1120 BID in patients with advanced non-small-cell lung cancer (NSCLC) who had failed at least one…
- Trial name
- NCT02182050
- Testing
- BIBF 1120 ES low dose, BIBF 1120 ES high dose
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Waldenstrom's Macroglobulinemia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to…
- Trial name
- NCT04274738
- Testing
- Mavorixafor, Ibrutinib
- Where
- 5 sites in United States, Greece
- Volunteers
- 16 people
- Sponsor
- X4 Pharmaceuticals
ccRCC, Clear Cell Renal Cell Carcinoma
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms
- Trial name
- NCT05119335
- Testing
- Oral NKT2152
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- NiKang Therapeutics, Inc.
Prostate Cancer
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
The goal of this clinical study is to determine the efficacy and safety of Seviteronel, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who…
- Trial name
- NCT02445976
- Testing
- Seviteronel: given orally once daily in 28-day cycles
- Where
- 21 sites in United States
- Volunteers
- 197 people
- Sponsor
- Innocrin Pharmaceutical
Advanced Solid Tumors
First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors
TP-0184 is a potent inhibitor of ALK2 or ACRV1 kinase, a constitutively active serine/threonine receptor kinase due to activating mutations or upregulated upstream signaling pathways.
- Trial name
- NCT03429218
- Testing
- TP-0184
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced and Selected Solid Tumors, AML
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
This is a multi-center, open-label, dose-finding, phase Ib study to estimate the maximum tolerated dose(s) (MTD(s)) and/or recommended dose(s) for expansion (RDE(s)) for the orally administered combination of BYL719 and MEK162.
- Conditions
- Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
- Trial name
- NCT01449058
- Testing
- BYL719, MEK162
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 139 people
- Sponsor
- Array BioPharma
Hepatocellular Carcinoma
A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
The purpose of this study is to investigate on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation
- Trial name
- NCT02210182
- Testing
- Oral Pentamidine
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Oncozyme Pharma Inc.
Non Hodgkin Lymphoma
Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL
The purpose of the study is to demonstrate that oral fludarabine phosphate is comparable to i.v. formulation used in combination with mitoxantrone in terms of efficacy, safety and risk/benefit profile
- Trial name
- NCT00185445
- Testing
- Fludarabine Phosphate (Fludara)
- Where
- 14 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Genzyme, a Sanofi Company
Oral Mucositis
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients…
- Trial name
- NCT03689712
- Testing
- GC4419 90mg
- Where
- 97 sites in United States, Canada and 1 more
- Volunteers
- 455 people
- Sponsor
- Galera Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.